Abstract
An osteotropic agent based on the human recombinant tumor necrosis factor alpha (TNF-alpha) has been designed for treatment of bone metastases. It represents a molecular construct containing yeast double- stranded ribonucleic acid (dsRNA) covered by the conjugate of polyanion dextran with TNF-alpha and bisphosphonate alendronic acid. This construct is characterized by the combination of substances possessing antitumor activity (TNF-alpha, dsRNA) and a vector molecule (bisphosphonate) providing tropism to hydroxyapatite, the main mineral component of the bone tissue matrix. The conjugation conditions were optimized and the conjugates of TNF-alpha and alendronic acid with dextran were synthesized. The molecular constructs were obtained by self-assembly, and the resultant complexes were separated by gel filtration on Sepharose CL-6B. The electrophoretic analysis has shown decreased mobility of dsRNA in the complex with the conjugate as compared to mobility of the original dsRNA. This confirms formation of the designed structures. Transmission electron microscopy confirmed the presence of particles with sizes of 30–40 nm in the drug preparation. Evaluation by the sorption/desorption method showed a higher affinity of TNF-alpha conjugates to hydroxyapatite as compared to original TNF-alpha molecules (from 1.0–1.8 mol/L vs. 0.3 mol/L of potassium phosphate buffer for desorption, respectively).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D., and Bray, F., Int. J. Cancer, 2015, vol. 136, pp. E359–386. doi 10.1002/ijc.29210
Hibberd, C., Cossigny, D.A.F., and Quan, G.M.Y., Cancer Growth and Metastasis, 2013, vol. 6, pp. 23–34. doi 10.4137/CGM.S11284
Shmelev, V.A., Interferon-gamma, factor nekroza opukholei, timozin-alfa1 – protevoinfektsionnye i protivoopukholevye tsitokiny i preparaty (Interferon-Gamma, Tumor Necrosis Factor, Thymosin-Alpha1 as Anti-Infective and Anti-Tumor Cytokines and Agents), Moscow: Medpraktika, 2008.
Masycheva, V.I., Lebedev, L.R., Danilenko, E.D., Sysoeva, G.M., and Gamalei, S.G., Rus. Patent no. 386447. Byul. Izobret., 2010, no. 11.
Chen, L., Ding, Y., Wang, Y., Liu, X., Babu, R., Ravis, W., and Yan, W., Int. J. Nanomed., 2013, vol. 8, pp. 138–145.
Lebedev, L.R., Alikin, Yu.S., Roslyakova, E.Yu., Podgornyi, V.F., Dubinkina, O.S., and Azaev, M.Sh., Biofarm. Zhurn., 2014, vol. 6, pp. 32–38.
Tracey, K.J., in The Cytokine Handbook, Thompson, A.W., Ed., 1994, pp. 289–304.
Lowry, O.H., Rosebrough, N.J., Farr, A.L., and Randall, R.J., J. Biol. Chem., 1951, vol. 193, pp. 265–275.
Lejeune, F.J. and Rüegg, C., Bull. Cancer, 2006, vol. 93, pp. E90–100.
URL: http://www.cancer.gov/drugdictionary/?CdrID= 39559, 2010.
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © L.R. Lebedev, E.D. Danilenko, Yu.V. Telegina, B.N. Zaitsev, 2016, published in Biomeditsinskaya Khimiya.
Rights and permissions
About this article
Cite this article
Lebedev, L.R., Danilenko, E.D., Telegina, Y.V. et al. An antitumor osteotropic agent based on tumor necrosis factor. Biochem. Moscow Suppl. Ser. B 10, 287–291 (2016). https://doi.org/10.1134/S1990750816030112
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1990750816030112